Background: Contemporary oxime antidotes to organophosphate poisoning cannot penetrate CNS to reactivate inhibited acetylcholinesterase. Result: Structural, in vitro optimization of ionizable hydroxyiminoacetamido amine acetylcholinesterase reactivators produced superior antidotal responses for VX, sarin, paraoxon and tabun exposed mice. Conclusion: Ionizable hydroxyiminoacetamido amines are promising centrally active acetylcholinesterase reactivators. Significance: A mechanism-based iterative refinement of acetylcholinesterase reactivation kinetics coupled with pharmacokinetic analyses yield efficient CNS penetrating antidotes.
SUMMARY
We present a systematic structural optimization of uncharged, but ionizable, N-substituted 2-hydroxyiminoacetamido alkylamine reactivators of phosphylated human acetylcholinesterase (hAChE) intended to catalyze the hydrolysis of organophosphate (OP) inhibited hAChE in the CNS. Starting with the initial lead oxime RS41A, identified in our earlier study, and extending to the azepine analogue RS194B, reactivation rates for OPhAChE conjugates formed by sarin, cyclosarin, VX, paraoxon and tabun are enhanced several fold in vitro. To analyze mechanism of intrinsic reactivation of the OP-AChE conjugate and penetration of the blood-brain barrier, the pH dependence of the oxime and amine ionizing groups of the compounds and their nucleophilic potential were examined by UV/VIS spectroscopy, 1 H NMR and oximolysis rates for acetylthiocholine and phosphoester hydrolysis. Oximolysis rates were compared in solution and on AChE conjugates and analyzed in terms of the ionization states for reactivation of the OP conjugated AChE. In addition, toxicity and pharmacokinetic studies in mice show significantly improved CNS penetration and retention for RS194B when compared with RS41A.
The enhanced intrinsic reactivity against the OP-AChE target combined with favorable pharmacokinetic properties resulted in great improvement of antidotal properties of RS194B compared to RS41A, and the standard peripherally active oxime, 2PAM. Improvement was particularly noticeable when pretreatment of mice with RS194B prior to OP exposure was combined with RS194B reactivation therapy following the OP insult.
Introduction
A recent spur of interest in centrally acting reactivators of organophosphate (OP) inhibited acetylcholinesterase (AChE; 1-6) reflects a compelling need for antidotal therapy capable of efficient reinstatement of CNS AChE activity in OP intoxicated individuals. Exposure to uncharged, lipophilic OPs from both pesticide and nerve agents leads to inhibition of peripheral and CNS AChE, within minutes of exposure, due to rapid OP diffusion through biological membranes of exposed individuals (7) . However, attention has been accorded primarily to the development of largely cationic reactivator antidotes in line with recognition that quaternary ammonium ligands have a clear preference for association with predominantly aromatic active center gorge of AChE (8 -14) . When administered in vivo, quaternary oxime reactivators largely remain in blood and peripheral tissue incapable of crossing the blood-brain barrier (BBB) and reactivating OP inhibited brain AChE (15) . An ideal centrally acting reactivator should thus combine properties of efficient reactivation and BBB penetration. Our initial approach was to develop a library of uncharged oxime reactivators amenable to protonation (1) and identify a lead structure. A reactivator, RS41A (Table 1) , comparable in its in vitro reactivating potency to standard pyridinium oxime reactivator 2PAM, was selected from a large synthetic library.
In this study we describe systematic variations of RS41A structure and a detailed evaluation of associated reactivating properties leading to several enhanced reactivators culminating in the several-fold improved azepine analogue RS194B.
By virtue of enhanced association with OP-hAChE conjugates, RS194B showed substantially improved in vitro reactivation kinetics compared to the initial lead RS41A. Moreover, the low toxicity of RS194B in the mouse animal model in combination with its enhanced intrinsic reactivity results in substantial improvement of its therapeutic properties compared to RS41A and the standard oxime, 2PAM. The improvement was particularly noticeable when pretreatment of mice with RS194B before OP exposure was combined with RS194B reactivation therapy following the OP insult. We describe here the mechanistic basis for this enhancement in terms of the intrinsic reaction constants and pharmacokinetic profiles.
Material and Methods
Enzyme. Highly purified monomeric hAChE was prepared as described earlier (1, 16) .
Organophosphates. Low toxicity, nonvolatile fluorescent methylphosphonates (FluMPs) (17) were used in in vitro experiments as analogues of nerve agents sarin, cyclosarin and VX. The Flu-MPs differ from actual nerve agent OPs only by structure of their respective leaving groups. Inhibition of hAChE by Flu-MPs results in OP-hAChE covalent conjugates identical to the ones formed upon inhibition with the corresponding volatile OPs. Paraoxon was purchased from Sigma-Aldrich (St. Louis MO, USA). Nerve agent OPs tabun, VX, sarin and soman used in in vivo experiments were purchased from NC Laboratory (Spiez, Switzerland).
Oximes. 2PAM (2-Pyridinealdoxime methiodide), MINA (monoisonitrosoacetone), and DAM (2,3-butanedione monoxime) were purchased from Sigma-Aldrich.
Preparation of novel oximes: NSubstituted 2-hydroxyiminoacetamides RS194B, RS194C, RS69N, RS218A, RS69L and RS191E were prepared from ethyl glyoxylate (1) in two steps (Scheme 1). Condensation with hydroxylamine provided ethyl glyoxylate oxime (2) followed by subsequent amidation with the corresponding primary amine.
In vitro oxime reactivation assays. hAChE activities were measured using a spectrophotometric assay (18) at 25 o C in 0.1 M sodium phosphate buffer, pH 7.4, containing 0.01% BSA and 1.0 mM substrate acetylthiocholine (ATCh). OP-hAChE conjugates were prepared and oxime reactivation performed (at 37 o C in 0.1 M sodium phosphate buffer, pH 7.4, containing 0.01% BSA) as described earlier (1, 16) . The first order reactivation rate constant (k obs ) for each oxime + OP conjugate combination was calculated by nonlinear regression (19) . The dependence of reactivation rates on oxime concentrations and determination of maximal reactivation rate constant k 2 , Michaelis-Menten type constant K ox and the overall second order reactivation rate constant k r were conducted as previously described (19 Computational molecular modeling. Interactions of oximes RS41A and RS194B within the active center gorge of VX inhibited hAChE were studied for the reversible complex and for the trigonal bipyramidal intermediate for the reactivation step using a simulated annealing molecular dynamics approach (21) . Covalent conjugates of hAChE ethylmethylphosphonylated at the active Ser203 were generated by pasting ethylmethylphosphonylated Ser203 of mouse AChE structure (pdb 2JGH) into the native wt hAChE structure (pdb 3LII) and subsequent semiempirical quantum mechanical adjustment of partial charges by InsightII suite (Accelrys, San Diego). All water molecules were removed from the pdb structures and a dielectric constant of 4 was used in calculation to mimic the interior of the hAChE active center gorge. In calculations for formation of the reversible complex, distances between oximate oxygen and the P atom of the VX conjugate were flexibly constrained to a distance between 0 and 3.00 Å. In trigonal bipyramidal intermediate calculations, the oximate oxygen was covalently linked to the P atom rehybridized to pentacoordinate geometry (21 Acute intramuscular (i.m.) toxicity (LD 50 ) was based upon 24 h mortality rates calculated according to Thompson (22) and Weil (23) . Each LD 50 was evaluated from the results obtained with four to six doses of a given oxime (dissolved in water plus a minute amount of HCl in order to form the corresponding hydrochloride salt).
Antidotal activity against OP poisoning was tested by giving male CD-1 mice the studied oximes i.m. (at the specified dose) together with atropine sulfate (10 mg/kg), one minute after subcutaneous (s.c.) OP administration (24, 25) . Stock solutions of nerve agents were prepared in isopropyl alcohol or in propylene glycol. Further dilutions were made in saline, immediately before use. Alternatively, mice were pretreated i.m. with oximes (at specified dose, but without atropine) 5 or 15 min before s.c. OP administration.
The combination of pretreatment and antidotal therapy was performed by i.m. pretreatment with oxime 15 min before s.c. OP administration followed by i.m. administration of oxime (dissolved in 5 mg/mL atropine sulfate) 1 min after OP.
The antidotal efficacy of oximes was expressed as protective index (PI) with 95% confidence limits and the maximal dose of organophosphate (MDP For experiments mice were divided into groups of three. In the pharmacokinetic studies, 80 mg/kg RS194B or 30 mg/kg RS41A oxime was administered i.m. as a single dose in the absence of OP. Three animals were injected for every time point analyzed. Brain and plasma were collected at each time point. Blood (~300 µl) was collected from the retro-orbital sinus of mice under isoflurane anesthesia into tubes containing EDTA, processed to plasma within 30 minutes of collection, and then stored frozen at ≤ -80°C (± 10°C).
Brains were collected and analyzed individually at each time point. Brain weight was documented for each animal prior to storage on dry ice. Brains were stored at ≤ -80°C (± 10°C) until analysis.
Concentration of the oxime in body compartments was determined by LC-MS using multiple reaction monitoring (MRM) electrospray ionization detection in positive ion mode.
Results
Systematic variations of RS41A structure. Our recent characterization (1) of a library of 135 uncharged, structurally diverse oximes revealed hydroxyimino acetamido amines as efficient reactivators of OP-hAChE conjugates. In particular, the selected lead structure RS41A appeared similar in reactivation potency to the standard reference oxime 2PAM. With the aim of better understanding structure/activity relationships of the hydroxyimino acetamido alkyl amine reactivators and specifically improving RS41A reactivation properties, we synthesized new reactivators by systematically modifying structure (Table 1) . In analyzing the alkylamine substituent attached to the 2-hydroxyimino acetamide, we distinguished two elements: the heterocycle "handle" and an intervening methylene "linker". Starting with the 2-hydroxyimino acetamido amine RS157A (no linker), ethyl, n-propyl and n-butyl linkers were introduced along with primary amine, dimethylamine, pyrrolidine, piperidine, azepane, azocane and bridged, polycyclic handles. Small amine and dimethylamine handles did not prove helpful resulting in largely inactive reactivators (the last four compounds in Table 1 ) irrespective of the associated linker length. Both ethyl and propyl linkers proved effective. Out of four pairs of compounds containing an identical handle the ethyl linker proved more efficient in two pairs (RS194B vs. RS194C and RS41A vs. RS69L) and the propyl linker in the other two pairs (RS251B vs. RS251A and RS191E vs. RS69N). Overall, the most effective reactivators were RS194B and RS191E where RS41A structure was extended either through linker or handle size, but combining both longer linker and larger handle (as in compound RS194C) was not productive. The further increase in handle size to either an eight membered azocane ring (RS251A and RS251B), bridged azepane (RS218A) or seven membered rings (RS2-57B) or by making it bicyclic yielded respectable, however not superior reactivators. Analysis of molecular volumes and solvent accessible surface areas for the N substituents (Table 1) suggests that the most efficient reactivators fall in the group of those having volume/surface area ratio between 0.87 and 0.92 suggesting that for this series of relatively similar compounds, a more spheroid rather than planar shape appears more productive. Intrinsic reactivities of all sixteen compounds from Table 1 reflected in their measured rates of ATCh oximolysis as well as calculated percents of respective oximate anions were similar emphasizing importance of the shape and charge distribution for the productive interaction with OPAChE conjugates leading to recovery of enzyme activity.
Reactivation kinetics of selected oximes in vitro.
To distinguish whether molecular recognition or intrinsic chemical reactivity of RS41A was dominant in influencing overall reactivation potency, we analyzed reactivation kinetics of seven leading congeners of RS41A and three reference oximes, 2PAM, MINA and DAM, and determined their individual reactivation constants k 2 and K ox (Table 2; Figure 1 ). In the analysis we assume that K ox mainly reflects initial reversible interaction of oxime reactivator with an OP-hAChE conjugate, whereas k 2 reflects the interaction of the reactivating oxime or oximate nucleophile with the phosphate moiety of the OP conjugated hAChE in leading to the trigonal bipyramidal intermediate for reactivation. Pairwise comparison of six reactivators containing the identical handle and different methylene linkers reveals that trigonal bipyramidal intermediate for the oximate reaction prefers shorter linker, whereas the initial reversible binding within the gorge appears frequently better for the propyl derivatives. Indeed, k 2 constants for the pairs RS194B vs. RS194C, RS69N vs. RS191E and RS41A vs. RS69L were frequently larger in respective ethyl derivatives, whereas K ox constants appeared smaller in respective propyl derivatives indicating stronger initial reversible interaction between an oxime and OP-hAChE. On the other hand, increases in the handle size from pyrrolidine to piperidine and azepane rings resulted primarily in smaller K ox values while k 2 constants remained largely unchanged. One could thus conclude that enhancement of reactivation rates observed for RS194B vs. initial lead RS41A results primarily from improved molecular recognition while preserving ability to form productive trigonal bipyramidal intermediate adducts. In further increasing size of handle from azepane to substituted tropane (RS194B to RS218A), a similar trend of lowering K ox can be observed for paraoxon and sarin conjugates. However, due to simultaneous loss of reaction efficiency (reflected in reduced k 2 constants), the overall reactivation efficiency of RS218A was not greater than that of RS194B. Hence, RS194B oxime, an azepane analogue of the initial lead RS41A, appears as several-fold better reactivator and significantly superior to the reference -ketoximes, DAM and MINA, primarily due to enhanced molecular recognition of OP-hAChE conjugates.
pK a determinations for lead oximes. The initial lead RS41A and the best uncharged reactivator RS194B include at least two groups ionizable in the physiologically relevant pH range, affecting their reactivation potencies. Deprotonation of the oxime group is assumed to be essential for the oxime nucleophilic reactivity, while protonation of the handle ring nitrogen (azepane or pyrrolidine) should improve molecular recognition of a largely aromatic and partly anionic active center gorge of OP-hAChE adducts. Our goal was therefore to determine pK a values of both ionizable groups for both RS41A and RS194B oximes. Initially UV/VIS spectroscopy was used to record change in UV spectra of both oximes in the pH range 1 -13 ( Figure 2 ). The increase in absorbance of both compounds at 270 nm results from deprotonation of the oxime hydroxyl enabling us to determine a common pK a value of 8.8 for both compounds ( Figure 2 ; Table  3 ).
Ionization states of the lead reactivator RS194B and the reference oxime 2PAM were studied in more detail using 1 H NMR spectrometry in D 2 O medium (Figures S1 and S2 and Figure 3 ). We focused on position and appearance of three peaks in RS194B spectrum ( Figure S1 ), the amido H peak present at ~ 7.65 ppm at pH 7.0 and two triplets coming from protons surrounding the azepane nitrogen and appearing at ~ 3.37 ppm and ~ 3.73 ppm at pH 7.0. Peak assignments were confirmed using the DQF-COSY spectra ( Figure S1B ). Due to dissociation of the proton or deuteron, all three peaks shift to lower field at higher pH. The singlet at ~7.65 ppm shifts slightly to ~7.59 ppm at pH 10 ( Figure 3A) . The triplet at ~3.38 ppm shifts slightly to ~3.28 ppm at pH 10 and becomes a complex multiplet ( Figure 3B ), whereas the triplet at 3.73 ppm shifts to 3.68 ppm ( Figure 3C ). Plotting the change of chemical shift in D 2 O as a function of pH yields three pK a values: 9.1 (equivalent to 9.1 -0.5 = 8.6 in H 2 O; (27) ) for loss of the imino hydrogen, and pK a 's 9.3 (8.8 in H 2 O) and 9.2 (8.7 in H 2 O) for the azepane and pyrrolidine protons on the nitrogens (Figures 3D, 3E and 3F; Table 3 ). Both ionizable groups should be largely protonated at the physiological pH of 7.4, thus rendering a cation dominant over the neutral, zwitterion and anionic species.
In the 1 H NMR spectrum of 2PAM in D 2 O, both the aldoxime CH peak and peaks of all aromatic protons shift simultaneously as a function of pH ( Figure S2 ). As expected only the N-methyl peak at 2.8 ppm did not shift (data not shown).
This indicates that ionization state of the oxime group affects delocalization of aromatic system of 2PAM.
This may influence the  orbital interactions between the pyridinium ring and aromatic residues in the AChE gorge and consequently binding orientation of the reactivator. Analysis of pH induced shifts of both the amido H peak (8.70 ppm at pH 7.0; Figure  S2C ) and the doublet of aromatic proton at position 6 (8.75 ppm at pH 7.0; Figure S2D ), reveal a D 2 O pK a value of 8.6 (8.1 in H 2 O) for the oxime group ionization (Figures S2E and S2F ; Table 3 ).
pH dependence of oxime nucleophilicity. The rates of oxime induced hydrolysis (oximolysis) of ATCh and Flu-MP analogue of VX measured spectrophotometrically and spectrofluorometrically were considered to be a measure of nucleophilic reactivity of an oxime. The pH dependence of ATCh oximolysis by RS41A, RS194B and 2PAM revealed respective pK a values of 9.0, 9.0 and 8.0 ( Figure S3 ) and pK a values of 8.9, 8.7 and 8.1 for VX Flu-MP oximolysis ( Figure S4 ), consistent with UV and 1 H NMR based pK a determinations ( Table 3) . As expected maximal oxime nucleophilicity was higher in oximates with higher pK a . However, at pH 7.4, the oxime-oximate pKa comes into play where 2-PAM would have a greater nucleophilic capacity because of the greater fraction of oximate species.
pH dependence of reactivation kinetics for lead oximes. Reactivation of VX-hAChE conjugate by RS41A and RS194B oximes as well as by RS186B and 2PAM measured in 0.1M phosphate buffers at pH 6.4, 7.4 and 8.4 reveals no systematic changes of the overall reaction rate (reflected in k r constant) (Table 4) , whereas the nucleophilic first order reactivation rate constant k 2 did show small increase with pH for all oximes. Consistent with its lowest pK a value the increase in k 2 was largest for 2PAM. However, while molecular recognition of 2PAM, reflected in K ox constant, increased at lower pH, it did not change appreciably for the other two oximes. Thus, the protonated forms of both RS194B and RS41A oximes that dominate in large ratios at pH 6.4 as well as pH 7.4 with amine pK a values around 8.9 (Table 3) did not bind to VX-hAChE conjugate as well as cationic 2PAM. The presence of a zwitterionic species at pH 8.4 (more than 50% of all forms for 2PAM and less than 50% for RS oximes) did not improve binding of RS oximes while it slightly compromised binding of 2PAM (Table 4 ; Figure 4) .
Acute oxime toxicity and oxime treatment of OP exposed mice. The acute i.m. toxicity for mice of RS41A and in particular the lead reactivator RS194B was found to be relatively low (Table 5 ). Both oximes were less toxic than standard reference oxime 2PAM (LD 50 =106 mg/kg), while RS194B was similarly toxic as HI-6 (LD 50 = 450 mg/kg; Kovarik et al., data not shown) known as the least toxic standard oxime antidote.
OP exposed mice treated with 125 mg/kg RS194B (a dose roughly equivalent to 25% of its LD 50 ) recovered significantly better from OP exposure than mice treated with equivalent dose of RS41A and notably better than animals treated with 2PAM, with paraoxon exposed mice being an exception ( Table 5 ). Treatment of VX exposed mice with lower RS194B doses equivalent to 10% its LD 50 (50 mg/kg) and 5% its LD 50 (25 mg/kg) yielded significant animal protection comparable to or better than 25% LD 50 dose treatment by 2PAM emphasizing the unique therapeutic efficacy of RS194B oxime (Table 6) .
Pretreatment of mice with RS194B either 5 min or 15 min prior to VX exposure provided notable protection effects only at the highest oxime dose applied (Table 6 ). However, combination of 15 min oxime pretreatment and post VX exposure therapy with 125 mg/kg RS194B produced exceptionally high protective index of 45, and ensured survival of all mice against VX dose of 31.8 multiples of its LD 50 that equals 900 µg/kg of VX. Combining pretreatment with therapy enhanced RS194B protective indices, albeit to a smaller extent, also for paraoxon, soman and tabun (Table 6) .
RS41A and RS194B pharmacokinetics in mice. Upon i.m. administration of a single dose of 80 mg/kg RS194B or 30 mg/kg RS41A maximal concentrations determined in plasma were 10 and 27 µg/ml, respectively (equivalent to 54 µM and 125 µM) observed at the initial collection time point ( Figure 5 ; Table S1 ). The time needed for maximal plasma concentrations to decay by half was 11 min and 12 min for RS41A and RS194B, respectively. The decay kinetics over this interval likely reflects the distribution into tissue from the plasma as well as total body elimination. The distinctly non-first order elimination of the RS compounds from plasma is consistent with a multi-compartmental analysis. Both compounds rapidly penetrated the blood-brain barrier (BBB). Maximal brain concentrations determined as 1.2 and 7.9 µg/ml (~6.5 µM and ~37 µM), respectively for RS41A and RS194B, reduced in half in 30 and 60 min. RS194B established between 15 min and 40 min post administration an apparent steady state concentration in brain, presumably due to the increased rate of brain accumulation and plasma declines in concentration (Table S1 ).
The resulting brain/plasma ratios at the t max were thus significantly, 2 -3-fold higher for RS194B (0.30) than for RS41A (0.12). Brain levels of both oximes, in particular RS194B, at the final time point (180 min; Figure 5 ) were higher than plasma concentrations suggesting that elimination from this tissue lagged compared to systemic peripheral clearance.
Discussion
The data presented herein are based on our recent revelation that N-substituted 2-hydroxyimino acetamidoalkyl amines, though devoid of a permanent cationic charge, can efficiently reactivate OP conjugated hAChE in vitro (1) . Formation of protonation equilibria around two ionizable groups in those oxime structures, an oxime group and an additional amine group results in coexistence of charged, zwitterionic and uncharged reactivator species around physiological pH values. While zwitterionic and cationic species have the best chance of productive interaction with OP-hAChE conjugates, the uncharged species can be expected to cross the blood-brain barrier delivering reactivator into CNS.
Our starting point for optimization was the structure of initially recognized lead hydroxyiminoacetamido alkyl amine reactivator, RS41A. Introduction of systematic structural modifications in both its aliphatic linker and heterocyclic handle led to oxime structures with several-fold improved potency for in vitro reactivation of four OP-hAChE conjugates culminating with new lead oxime structure RS194B. Not only were we able to design a more efficient reactivator, but through detailed analysis of reactivation kinetics, we obtained insights into regulatory structural constraints imposed by varying geometries of OP-hAChE conjugates. Reversible binding of a reactivator leading to progressive reactivation is thus facilitated by propyl linker and a bridged azepane heterocycle, while optimal geometry of AChE-OP-Oxime trigonal bipyramidal intermediate is achieved with ethyl linker. The greater in vitro reactivation rate of RS194B is therefore largely a reflection of its improved molecular recognition i.e. better binding to OP-hAChE conjugates as indicated by smaller K ox constants, while maintaining similar k 2 constants, in comparison to RS41A. This effectively means that improved oxime * OPhAChE interactions in the reversible complex were also preserved in the subsequent reaction trigonal bipyramidal intermediate. Computational molecular modeling of two reaction steps for RS41A and RS194B oximes consistently reveals more pronounced similarity in geometries of reversible complex and trigonal bipyramidal intermediate for RS194B oxime, and not with RS41A oxime (Figure 6 ). Additionally modeling suggests that the main anchoring point of both RS41A and RS194B oximes in interaction with VX-hAChE is the aromatic amino acid cluster of the AChE peripheral site.
Analysis of ionization states of RS194B by UV spectroscopy, 1 H NMR spectrometry and pH dependence of oximolysis reveals that both oxime group and amino group in the reactivator handle have pK a constants in the range between 8.6 and 9.0. At physiological pH 7.4 therefore more than 90% of the compound exists in the protonated, cationic form. That seems to be reflected in reasonable in vitro reactivation kinetics where the initial reversible binding is improved for RS194B vs. RS41A (lower K ox ) while maintaining respectable reactivity (a small decrease in k 2 ). A low fraction of oximate is thus counteracted by high nucleophilicity ( Figure S3 ) and preferred for CNS reactivators due to lower ionization of the oximate facilitating BBB penetration.
In spite of the suggestion that reactivators with lower oxime pK a may be intrinsically more reactive at physiological pH in the absence of enzyme (Figure 7; 26) , their overall reactivation potency expressed by constant k r was not found to correlate closely with the oximate pK a (in the wide pK a range 6.5 -10.1) for reactivation of any of OP-hAChE conjugates analyzed individually ( Figure S5 ) or as an average (Figure 7) . The linear increase of the maximal rate of reactivation log k 2 with the increase in pK a , observed for five studied reactivators ( Figure S6E ), however reveals a greater dependence of reactivator nucleophilic strength for reactivity of AChE-OP-Oxime trigonal bipyramidal intermediate when compared to fractional availability of oximate anion at physiological pH determined by the oximate pK a . This observation may indicate an effective proton extraction mechanism for oxime reactions in the hAChE active center gorge. On the other hand domination of the protonated amine at pH 7.4, influences the capacity of RS194B to enter the CNS. Nevertheless, pharmacokinetic studies in mice indicate that both RS194B and RS41A oximes penetrate CNS quickly and can be found there at up to 37µM and 6.5 µM concentrations which are ~12 -30% of corresponding plasma concentrations.
Very good antidotal actions of RS194B in treatment of OP exposed mice relative to RS41A or 2PAM treatments undoubtedly result from its improved intrinsic reactivation potency combined with its lower toxicity and superior pharmacokinetic profile including faster CNS penetration and longer retention. However, a favorable antidotal action of RS194B was noticeable even at doses equivalent to 5% and 10% its LD 50 value. RS194B was most efficient in therapy of VX, sarin and paraoxon exposed mice, where it was superior to both RS41A and to a standard reactivator 2PAM (except for paraoxon intoxication). While RS194B, when given solely as a pretreatment modality, produced limited prophylactic protection to subsequent OP exposure, consistent with its relatively low binding affinity for AChE conjugates (large K ox values), the combination of pretreatment and therapy at the highest RS194B dose resulted in outstanding antidotal efficiency reflected in the protective index of 45.
Several classes of novel compounds have been recently suggested as promising centrally active reactivators of OP exposed hAChE. Two nonquaternary pyridine aldoxime phenyltetrahydroisoquinoline derivatives directed to interact with the AChE peripheral site showed outstanding potency for in vitro reactivation of VX and tabun conjugated hAChE (2) . Thus, uncharged, extended ligands with high affinities for the peripheral site form an alternative means of directing nucleophiles to the organophosphate conjugated active center (28). The overall second order rate constant (k r ) for reactivation of VXhAChE conjugate by phenyltetrahydroisoquinoline derivatives was an order of magnitude larger than the corresponding RS194B constant, in spite of nearly an order of magnitude smaller maximal reactivation rate constant (k 2 ) and largely due to their high apparent affinity for VX-hAChE conjugate (K ox = 6 -47 µM). However, these compounds lack pharmacokinetic, toxicity and efficacy analyses.
A similar series of α-ketoaldoxime derivatives of polycyclic peripheral site directed ligands also exhibited initial promise in reactivation of VX and sarin conjugated hAChE, whereas tabun-hAChE conjugate reactivation was less efficient (3). Finally, several amidine based oximes indicated positive in vitro and in vivo initial properties for reactivation of hAChE inhibited by charged or less volatile nerve agent analogues (4) . While in vitro reactivation approached 2PAM reactivation levels, in vivo efficacy for treatment of nerve agent exposed mice is difficult to assess since low toxicity nerve agent surrogates were used as toxicants.
In summary, this study presents uniquely comprehensive characterization of a novel series of N-substituted 2-hydroxyimino acetamido alkylamine reactivators of nerve agent conjugated hAChE. Through systematic steps of structural modifications, we refined the initial lead RS41A into a superior RS194B reactivator of VX, sarin, paraoxon, cyclosarin and tabun conjugated hAChE, both in vitro and in vivo.
Cyclosarin has yet to be tested in vivo. Outstanding intrinsic reactivation potencies of this oxime resulting in part from its favorable interaction with the peripheral site of AChE, in combination with its low toxicity results, provide the lead for a panreactive antidote for the treatment of OP exposed mice, either post-exposure or in combination of prophylactic and antidotal oxime treatments of OP exposed animals. Free energy relationships between nucleophilic reactivities and oxime group ionization states of selected oxime reactivators. Rate constants (k) of maximal pH dependent ATCh oximolysis (black line and circles), oximolysis at pH 7.4 (grey line and circles) and an average overall rate constant k r (M -1 min -1 ) for oxime reactivation of VX, sarin, cyclosarin and paraoxon inhibited hAChE (white diamonds) in relation to pK a values determined for reactivator oxime groups. The lead reactivator RS194B data is indicated by cross-haired symbols. k r for RS174C and RS150D (not extensively studied in this series) were extrapolated from reactivation rates determined at single (0.67 mM) oxime concentration.
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Oxime
Oxime Table 6 . Combination of therapy and pretreatment of OP exposed mice with oxime RS194B at doses equivalent to 25%, 10% or 5% its LD 50 dose of 500 mg/kg (cf . Tables S2 -S6 ). Protective index is the ratio of OP LD 50 for OP exposed animals treated with oxime and for animals given OP alone. Maximal dose of poison (MDP), a highest multiple of OP LD 50 fully counteracted by the oxime, is given in parentheses. Oximes in therapy (but not in pretreatment) were administered together with atropine. 
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